Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker AnalysisNabil F. Saba, Christine H. Chung, Soumon Rudra et al.|Clinical Cancer Research|2024Cited by 10
Inflammatory biomarkers have a prognostic role in patients with metastatic castration‐resistant prostate cancer treated with Lutetium‐177–PSMA‐617Margo B. Gerke, Mehmet Asım Bilen, Angelo Marra et al.|Cancer|2026Cited by 2
Supplementary Table S1 from Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker AnalysisNabil F. Saba, Christine H. Chung, Ritu Chaudhary et al.|Unknown|2024Cited by 0
Data from Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker AnalysisNabil F. Saba, Christine H. Chung, Ritu Chaudhary et al.|Unknown|2024Cited by 0
Supplementary Table S2 from Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker AnalysisNabil F. Saba, Christine H. Chung, Ritu Chaudhary et al.|Unknown|2024Cited by 0